Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review
Anna Gonzalez,1 Quinn Kistenfeger,2 Casey M Cosgrove1 1Division of Gynecologic Oncology; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH, USA; 2Division of Obstetrics & Gynecology; The Ohio State University, Columbus, OH,...
Saved in:
| Main Authors: | Gonzalez A, Kistenfeger Q, Cosgrove CM |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | International Journal of Women's Health |
| Subjects: | |
| Online Access: | https://www.dovepress.com/patient-selection-for-the-use-of-niraparib-in-advanced-ovarian-cancer--peer-reviewed-fulltext-article-IJWH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
by: Whitney S Graybill, et al.
Published: (2024-12-01) -
Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study
by: Dana M. Chase, et al.
Published: (2025-01-01) -
Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01) -
Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis
by: Ning Jin, et al.
Published: (2025-03-01) -
Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01)